Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Articles online first > Minerva Gastroenterologica e Dietologica 2020 Dec 10

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Gastroenterologica e Dietologica 2020 Dec 10

DOI: 10.23736/S1121-421X.20.02821-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Risk stratification in primary sclerosing cholangitis

Giacomo MULINACCI 1, 2, Laura CRISTOFERI 1, 2, Andrea PALERMO 1, 2, Martina LUCÀ 1, 2, Alessio GERUSSI 1, 2, Pietro INVERNIZZI 1, 2, Marco CARBONE 1, 2

1 Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 2 European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy


PDF


Primary Sclerosing Cholangitis (PSC) is a chronic liver disorder commonly affecting young patients and associated with uncertain prognosis and elevated risk of end-stage liver disease and hepatobiliary cancer. Rate of progression in PSC is heterogeneous and accurately predicting the disease course is of paramount importance to clinical practice and interventional trial design. So far, efforts have brought to the development of models looking at short-to-middle-term outcome using composite models including clinical, laboratory, radiological and histological parameters with limited performance. In the era of whole genome sequencing and digital innovation, the time is ripe for the development of stratified medicine in PSC. Efforts should be directed toward developing wellphenotyped cohorts of patients with longitudinal follow-up across sustained periods of time, application of novel image-processing technology, and biomarker discovery using multi-omics platforms.


KEY WORDS: PSC; Risk-stratification; Biomarkers; Imaging

top of page